Department of Neurosurgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.
J Neurooncol. 2020 Jan;146(2):265-273. doi: 10.1007/s11060-019-03388-5. Epub 2020 Jan 3.
Neurofibromatosis type 2 (NF2) patients uniformly develop multiple schwannomas. The tumor-microenvironment (TME) is associated with hypoxia and consists of immunosuppressive cells, including regulatory T cells (Tregs) and tumor-associated macrophages (TAMs). The hypoxic TME of NF2 schwannomas remains unclear. In addition, no comparative study has investigated immunosuppressive cells in NF2 and sporadic schwannomas.
In 22 NF2 and 21 sporadic schwannomas, we analyzed the immunohistochemistry for Ki-67, hypoxia-inducible factor-1α (HIF-1α), vascular endothelial growth factor receptor 1 (VEGFR1) and VEGFR2, platelet derived growth factor receptor-beta (PDGFR-β), programmed cell death-1 (PD-1)/ programmed cell death ligand-1 (PD-L1), Foxp3, CD163, CD3, and CD8 to assess the immunosuppressive TME.
Most vessels in sporadic schwannomas exhibited slight or negative VEGFR1 and 2 expressions with pericytes coverage. In contrast, large vessels in NF2 schwannomas exhibited strong VEGFR1 and 2 expressions without pericytes. The number of CD3, CD8, and CD163 cells was significantly higher in NF2 schwannomas than in sporadic ones. The expression of PD-L1 and nestin positive cell ratio was higher in NF2 schwannomas than that in sporadic ones. The number of CD163 cells, nestin positive cell ratio, and HIF-1α expression were significantly associated with shorter progression-free survival in NF2 schwannomas.
This study presents the clinicopathological features of the differences in immunosuppressive cells and the expression of immune checkpoint molecules between NF2 and sporadic schwannomas. Hypoxic TME was first detected in NF2-schwannomas, which was associated with the tumor progression.
神经纤维瘤病 2 型(NF2)患者普遍会出现多发性神经鞘瘤。肿瘤微环境(TME)与缺氧有关,其中包括免疫抑制细胞,如调节性 T 细胞(Tregs)和肿瘤相关巨噬细胞(TAMs)。NF2 神经鞘瘤的缺氧 TME 尚不清楚。此外,尚无比较研究调查 NF2 和散发性神经鞘瘤中的免疫抑制细胞。
在 22 例 NF2 和 21 例散发性神经鞘瘤中,我们分析了 Ki-67、缺氧诱导因子 1α(HIF-1α)、血管内皮生长因子受体 1(VEGFR1)和 VEGFR2、血小板衍生生长因子受体-β(PDGFR-β)、程序性细胞死亡-1(PD-1)/程序性细胞死亡配体 1(PD-L1)、Foxp3、CD163、CD3 和 CD8 的免疫组化染色,以评估免疫抑制性 TME。
散发性神经鞘瘤中的大多数血管表现出轻微或阴性的 VEGFR1 和 2 表达,并伴有周细胞覆盖。相比之下,NF2 神经鞘瘤中的大血管表现出强烈的 VEGFR1 和 2 表达,而没有周细胞。NF2 神经鞘瘤中 CD3、CD8 和 CD163 细胞的数量明显高于散发性神经鞘瘤。NF2 神经鞘瘤中 PD-L1 和巢蛋白阳性细胞比例高于散发性神经鞘瘤。NF2 神经鞘瘤中 CD163 细胞的数量、巢蛋白阳性细胞比例和 HIF-1α 表达与无进展生存期显著相关。
本研究首次报道了 NF2 和散发性神经鞘瘤之间免疫抑制细胞和免疫检查点分子表达的临床病理特征差异。在 NF2 神经鞘瘤中首次检测到缺氧 TME,其与肿瘤进展有关。